Post X-Waiver: Improving Buprenorphine Access at the Community Pharmacy
This knowledge-based session builds upon previous presentations reviewing the commonly encountered barriers to buprenorphine access at community pharmacies including key findings of the 2021 statewide pharmacist buprenorphine survey. The program will address common barriers including controlled substance management, knowledge deficits, and perceptions of stigma and diversion. Changes in buprenorphine availability related to removal of X-waiver and the revised DEA telehealth prescribing rule will be discussed. To initiate a change in practice and improve buprenorphine access, the discussion will include examples of specific strategies for resolution including effective communication with patients and collaboration with care team members. By participating in this program, pharmacists will increase their knowledge of buprenorphine for OUD, and willingness to provide OUD education and medication therapy in their community pharmacy practice.
1 Available Credit – Meets DEA SUD Training Requirements:
- Pharmacy CEU
- MCBAP credit pending
- Social Work CEU credit pending
- CME credit pending
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of MyMichigan Health and Michigan Opioid Collaborative. MyMichigan Health is accredited by the Michigan State Medical Society to provide continuing medical education for physicians. MyMichigan Health designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity. This training meets the new DEA SUD training requirements.
- Victoria Tutag-Lehr, PharmD
Click here or scan the QR Code below to register for this webinar!